Know Cancer

or
forgot password

A Non-interventional Multicenter Study of First-line AvastinĀ® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer

Thank you

Trial Information

A Non-interventional Multicenter Study of First-line AvastinĀ® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer


Inclusion Criteria:



- Adult patients, age >/=18 years

- Proven metastatic colorectal carcinoma

- Patients have measurable disease

- Patients are eligible to receive first-line Avastin

- Patients have signed data release form

Exclusion Criteria:

- Contra-indication to receive Avastin according to the local labeling

- Participation in a clinical study within 30 days prior to enrolment

- Patients have any other primary cancer

- Concomitant treatment with other biologics

- History of other malignant disease in the past 5 years except basal cell carcinoma

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-free survival in a real life setting assessed by computer tomography

Outcome Time Frame:

Approximately 2 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Lebanon: Ministry of Public Health

Study ID:

ML25198

NCT ID:

NCT01266564

Start Date:

September 2010

Completion Date:

February 2014

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms

Name

Location